about
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerNew target genes of MITF-induced microRNA-211 contribute to melanoma cell invasionThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerPigmy MicroRNA: surveillance cops in Therapies kingdomIntegration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasionmicroRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers.Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growthMicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastomaIn-depth characterization of microRNA transcriptome in melanoma.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary FibrosisMicroRNA-650 in a copy number-variable region regulates the production of interleukin 6 in human osteosarcoma cells.Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells--Evidence of unique microRNA cargos.MicroRNAs as Biomarkers in Cancer.Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cellsOncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions.C-terminal binding proteins are essential pro-survival factors that undergo caspase-dependent downregulation during neuronal apoptosis.Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer.MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients.The three M's: melanoma, microphthalmia-associated transcription factor and microRNA.MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy.Aberrations in the micro-RNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma.miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.MicroRNAs in melanocyte and melanoma biology.miR-214: a potential biomarker and therapeutic for different cancers.miRNAs in melanoma: a defined role in tumor progression and metastasis.Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma.MicroRNAs in melanoma development and resistance to target therapy.The role of microRNAs in cancer susceptibility.MicroRNAs as molecular classifiers for cancer.There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.miRNAs and sports: tracking training status and potentially confounding diagnoses
P2860
Q54995613-5606FBD1-956A-4BE8-AB16-3D48A13934A8Q54995628-07775510-86D7-4250-BCE2-690D208472FFQ54995632-5511E0C4-6A38-496E-8AA9-C8F7ED61C69EQ54995633-8C44B14E-2761-4BFF-8E45-9E8AB7CA670FQ54995638-E9784A56-A1C5-4F02-8036-63C43343953CQ54995640-0EDC8F1D-690E-4791-AF29-6A23184AE509Q54995649-AF085192-9A6C-43DA-9723-D256B0D06809Q54995650-E4B690DF-3A86-4C10-A266-0A8CE09457EFQ54995652-36D39FA5-1D07-41A1-99A8-0F827D48B272Q54995657-8850C5D3-B3A2-4D95-8117-EADC43CBF5D6Q54995660-2AFA81FE-5006-452D-994A-094A719FD8C8Q54995662-A66B3DD5-9465-40BC-A2F3-BF48E4F0FD7BQ54995664-5C3EBFFF-E2EC-4E7C-AC64-6AA596753108Q54995665-E5FED4E4-7462-4D2F-8039-005D914DE793Q54995666-5773E8A4-4CFD-4090-BBCF-7AB747DFC4A5Q54995667-A98B066A-46E7-4905-A0EA-3B33F60E7462Q54995668-F67B56D1-92A7-4007-8C37-236BFE2F230FQ54995672-8AF77064-2FD8-4A81-8AA9-0E2889917D8AQ54995673-EBD53B68-33B2-4AAA-A58C-D72CF0A4A8B4Q54995675-C7616C01-3E27-4342-B5EA-33D79FC77072Q54995676-0E7FCB34-364D-4CFB-9D0E-35251F7ED45DQ54995692-A89F0E3F-AC6B-4586-90E9-8A84A0F51BC1Q54995695-9D581A6F-E033-4081-84EA-4A0CB55E0EECQ54995698-10D4AA39-C705-4372-99E6-CC702ECDCEB1Q54995773-211716B6-F2B5-43D3-9A66-72538FB84DD7Q54995776-49AA2815-B06B-4126-87B6-503E1D33993CQ54995778-21B708DB-0B99-4557-9BAA-57A868AF1C74Q54995783-E5400C59-4061-42B1-9BEE-8BABA906D15DQ54995788-8F8BDAED-9336-413D-A5D6-ED87A984CC3FQ54995790-BEEBE062-C2E0-4E37-8C27-7AD44C751B38Q54995791-9FAC6C6C-B8D0-4B9E-A4FA-8A151D218110Q54995795-B035510F-3758-487D-A6B7-06A8EC922D85Q54995799-17F10979-8AD9-4604-BD44-D9C17E40B381Q54995809-CAA8D53D-D1FC-45CF-B070-509D60CAEC2CQ54995822-BBC88806-E748-4979-AD24-6C76670A0404Q54995827-CE86AD91-239C-4803-801A-91FA1F1A313FQ54995828-54983315-ED4C-4A5D-A416-ED633F054308Q54995830-22FB924F-13A4-4C55-9611-A8BED8370DB2Q54995834-E9801CF1-6D65-4706-B195-E5A793FDF683Q54995838-48C3C707-39E7-484A-8510-77960DEA6EC2
P1343
Q26829794-007AC2D6-EB22-4181-A010-5CB6182C58BEQ28536746-C4F02C20-49AA-4483-802A-314B973C59D3Q28729202-27C3A2BB-37BB-4CE7-A2D8-DCB3CA8185E8Q28818470-BA8124F1-A96D-4814-A48D-D44B15A532F2Q33670486-3F3B909D-946E-4220-8BCE-40DFD958E8F3Q33802900-43BB5217-21A2-4B51-A992-0623E39F7988Q34215802-435E7FB3-AE57-434B-8949-830ED187DFAEQ34252329-E6B4E87B-F968-4308-A0B3-AB6A47B64AD1Q34289902-EE3A11CF-6B86-4453-94A8-7B3953F6172EQ34450694-E87F4E4B-4832-4013-B06E-CCA28FEFA697Q34633885-0C90FAA2-7A56-497B-821E-487E51570784Q34673170-746974AB-98C6-4AC8-9DB4-1661E3CCD271Q34736639-23B8DB2B-4248-4779-BB75-16E517582039Q34984013-C5FD1819-F7CF-4825-B705-E98F0E339F51Q35147597-B7F63C52-AF71-43CC-8F94-EB6E30BBF87BQ35792806-8E9D9579-3231-4F60-B35F-D7F25DB6F09BQ36059848-71A850A5-2DBF-4345-AF4D-168DB5A372ABQ36085941-A546EC95-9D0E-44FF-83D9-B595E624325CQ36191656-FE9119B6-F70B-4314-B5DB-78A6B6ABC71EQ36335261-9FFCCC6E-9129-4225-9268-424B5A0BB32BQ36403142-BCBA2202-9984-40BA-B4EF-2B6EA3786AB6Q36778838-43D1F841-A54D-4E0F-800A-2773C3F1A903Q37216918-88F9722A-F47B-4921-8E6E-E243BC138D99Q37354017-38F0FA94-9C4F-4EF5-A782-6D646AB23328Q37562273-42D36B13-9B58-4537-8A9F-0B82C16837C5Q37588073-567C8B56-6B00-4222-BDC0-2336F9DE10F9Q37946457-A160E9A8-60F4-4410-81FE-24B497AF9C29Q38018308-7B469460-E2E6-4152-88F1-B6D9C0E5A930Q38041704-FC570257-785C-4D92-930F-E6FD58BA74B9Q38138933-57C80C13-2518-4456-9EEC-C5A244839EA3Q38291001-80563076-845C-4E86-B194-471824F13ADBQ38319595-24222C35-BD71-4FC6-B2B0-7F0FF20C840BQ38617229-4665C228-CE82-4A6A-8AFE-88DDD3D9CC48Q38993964-860147D8-78BE-409D-AB6A-8A61BF466505Q39101272-E43225B1-A1A0-4BA7-B429-06EAC679FE8CQ39558389-0BC0B410-B9BE-4CA4-9DF1-44A79ED7E8AFQ39676479-6630A5CF-9455-4F35-852A-CE6DA18CFCE0Q40150714-B11242A6-DDE6-4DBE-8007-C25F645C3C9DQ41025694-602EBA0F-9A14-4E73-B18B-E070D992A877Q42142151-09D7BE7C-267E-4C33-BA0A-7E39F82D24AD
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MicroRNA signatures differentiate melanoma subtypes.
@ast
MicroRNA signatures differentiate melanoma subtypes.
@en
MicroRNA signatures differentiate melanoma subtypes.
@nl
type
label
MicroRNA signatures differentiate melanoma subtypes.
@ast
MicroRNA signatures differentiate melanoma subtypes.
@en
MicroRNA signatures differentiate melanoma subtypes.
@nl
prefLabel
MicroRNA signatures differentiate melanoma subtypes.
@ast
MicroRNA signatures differentiate melanoma subtypes.
@en
MicroRNA signatures differentiate melanoma subtypes.
@nl
P2093
P2860
P4510
P50
P356
P1433
P1476
MicroRNA signatures differentiate melanoma subtypes.
@en
P2093
David Tuck
Elcie Chan
Elena Ratner
Kathleen Hoyt
Rajeshvari Patel
Ruth Halaban
Sebastian Szpakowski
Sirie Godshalk
Stephan Ariyan
Sunitha Nallur
P2860
P304
P356
10.4161/CC.10.11.15777
P577
2011-06-01T00:00:00Z